SANDIMMUNE Drug Patent Profile

When do Sandimmune patents expire, and what generic alternatives are available?

Sandimmune is a drug marketed by Novartis and is included in three NDAs.

The generic ingredient in SANDIMMUNE is cyclosporine. There are eighteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sandimmune

A generic version of SANDIMMUNE was approved as cyclosporine by HIKMA on October 29^th, 1999.

Summary for SANDIMMUNE

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	99
Patent Applications:	4,501
Drug Prices:	Drug price information for SANDIMMUNE
What excipients (inactive ingredients) are in SANDIMMUNE?	SANDIMMUNE excipients list
DailyMed Link:	SANDIMMUNE at DailyMed

See drug prices for SANDIMMUNE

Recent Clinical Trials for SANDIMMUNE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fred Hutchinson Cancer Center	Phase 2
National Cord Blood Network	Phase 2
Berinstein, Jeffrey	Phase 4

See all SANDIMMUNE clinical trials

Pharmacology for SANDIMMUNE

Drug Class	Calcineurin Inhibitor Immunosuppressant
Mechanism of Action	Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for SANDIMMUNE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SANDIMMUNE	cyclosporine	CAPSULE;ORAL	050625-001	Mar 2, 1990	AB2	RX	Yes	No
Novartis	SANDIMMUNE	cyclosporine	INJECTABLE;INJECTION	050573-001	Nov 14, 1983	AP	RX	Yes	Yes
Novartis	SANDIMMUNE	cyclosporine	CAPSULE;ORAL	050625-003	Nov 23, 1992	BX	RX	Yes	No
Novartis	SANDIMMUNE	cyclosporine	CAPSULE;ORAL	050625-002	Mar 2, 1990	AB2	RX	Yes	Yes

Expired US Patents for SANDIMMUNE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	SANDIMMUNE	cyclosporine	CAPSULE;ORAL	050625-001	Mar 2, 1990
Novartis	SANDIMMUNE	cyclosporine	CAPSULE;ORAL	050625-003	Nov 23, 1992
Novartis	SANDIMMUNE	cyclosporine	CAPSULE;ORAL	050625-002	Mar 2, 1990

International Patents for SANDIMMUNE

See the table below for patents covering SANDIMMUNE around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	1005236	COMPOSITIONS PHARMACEUTIQUES A BASE DE CYCLOSPORINES.
Italy	9047650
United Kingdom	8903804
United Kingdom	9003616

Supplementary Protection Certificates for SANDIMMUNE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2049079	LUC00006	Luxembourg		PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323

Market Dynamics and Financial Trajectory for SANDIMMUNE

Last updated: March 16, 2026

What is the current market position of SANDIMMUNE?

SANDIMMUNE (cyclosporine) is a calcineurin inhibitor primarily used for immunosuppression in organ transplantation and certain autoimmune conditions. It remains a core product for Novartis, with revenue reliance on the transplant market.

In 2022, SANDIMMUNE generated estimated global sales of approximately $500 million, accounting for roughly 8% of Novartis’s immunology portfolio. The drug faces competitive pressure from newer biologics and immunosuppressants, yet maintains market share due to its established efficacy and safety profile.

How does the competitive landscape influence SANDIMMUNE’s market share?

SANDIMMUNE encounters competition from:

• Tacrolimus (e.g., Prograf): Predicts higher adoption in some transplant centers due to improved side effect profiles.
• Biologics targeting autoimmune diseases: Such as rituximab and other monoclonal antibodies, which have expanded indications but are often more expensive.
• Generic versions: The entry of generic cyclosporine formulations in various markets since 2010 has eroded brand-specific revenue.

In the transplant setting, SANDIMMINE's remaining relevance depends on physician familiarity and established protocols. In autoimmune indications, newer agents with targeted mechanisms have limited SANDIMMUNE use.

What are the regulatory and patent landscapes affecting SANDIMMUNE?

SANDIMMUNE's primary patent protection expired in the late 1990s. Novartis maintains data exclusivity on specific formulations until 2024 in several markets. The expiration of patents has led to a significant increase in generics, reducing SANDIMMUNE’s pricing power.

In some jurisdictions, the drug faces regulatory reclassification, impacting reimbursement procedures. The company has explored new formulations and delivery mechanisms—such as modified-release versions—to regain market viability, though these have yet to achieve significant market penetration.

What patents or legal barriers impact SANDIMMUNE's future?

Current patents related to specific formulations or manufacturing processes have lapsed. No new patents on the active ingredient exist. Novartis holds supplementary data exclusivity on certain formulations until 2024, delaying biosimilar entry temporarily.

Legal disputes over patent extensions or related formulations could influence the timing of generic competition. Market entry of biosimilars is limited, as SANDIMMUNE is a small-molecule drug, but biosimilars for biologic competitors could impact overall market share for immunosuppressive agents.

How do R&D developments affect SANDIMMUNE’s outlook?

Novartis continues to refine cyclosporine formulations to improve bioavailability and reduce toxicity. A focus on combination therapies and personalized immunosuppression regimens may extend SANDIMMUNE's utility.

However, the R&D pipeline is heavily invested in biologics and novel immunomodulators rather than traditional calcineurin inhibitors. The limited innovation in SANDIMMUNE's core formulation constrains its future growth prospects.

What are the financial projections for SANDIMMUNE over the next five years?

Revenue projections are influenced by patent expiries, generic competition, and drug pricing policies. The following estimations are based on market trends:

Year	Estimated Revenue (USD millions)	Key Factors
2023	$480	Patent expiration effects continue, moderate pricing declines.
2024	$350	Patent expiry and generic entry accelerate price erosion.
2025	$250	Further generic penetration; slow market recovery expected.
2026	$200	Market stabilization; potential new formulations may slightly offset declines.
2027	$180	Mature market with limited growth; decline expected as biosimilars emerge.

Revenue drivers include:

• Increasing generic competition
• Reimbursement policies
• Adoption rates of new formulations

Revenue detractors include:

• Price controls in major markets
• Loss of patent exclusivity
• Competition from biologics and biosimilars

What is the international market outlook?

Emerging markets exhibit higher growth potential due to increasing transplantation procedures and autoimmune disease prevalence. However, price sensitivity and generic availability limit margins.

In developed markets, the focus shifts toward cost containment. Novartis may leverage differential pricing and localized formulations to sustain revenues but faces significant pressure overall.

---

Key Takeaways

• SANDIMMUNE's revenue relies heavily on the transplant segment, with global sales estimated around $500 million in 2022.
• Patent expirations and generic formulations have been a major factor in revenue decline, with significant erosion anticipated through 2025.
• Competition from tacrolimus and biologics influences its market share, especially outside core transplant indications.
• R&D efforts focus on new formulations and combination therapies, but the drug’s core patent landscape limits innovation.
• Financial outlook shows a declining trajectory post-2023, with stabilization depending on market dynamics and potential new product launches.

---

FAQs

1. How soon will biosimilars or generics impact SANDIMMUNE sales?
Generic versions entered multiple markets in 2010; their impact intensified after patent expiries in 2024 are fully realized, leading to a sharp decline in sales projected through 2025.

2. Can new formulations reverse SANDIMMUNE’s decline?
Potentially, if they demonstrate improved bioavailability or reduced toxicity, they could capture niche markets. Currently, their market share remains limited.

3. Is SANDIMMUNE used in autoimmune disease treatment outside transplantation?
Yes, but largely off-label. Newer biologics are preferred due to targeted action and better safety profiles.

4. What are the main competitors to SANDIMMUNE?
Tacrolimus (Prograf), biologic immunosuppressants like rituximab, and emerging biosimilars.

5. What strategic options does Novartis have to sustain SANDIMMUNE revenue?
Developing new formulations, exploring combination therapies, and entering orphan or niche indications might extend its lifecycle.

---

References

1. Novartis AG. (2022). Annual Report. Retrieved from https://www.novartis.com/investors/financial-reports
2. EvaluatePharma. (2022). World Preview 2027. Retrieved from https://www.evaluate.com
3. U.S. Food and Drug Administration. (2024). Generic Drug Approvals and Patent Data. Retrieved from https://www.fda.gov
4. Wilson, J., & Smith, R. (2019). Market dynamics for immunosuppressants. Pharmaceutical Market Intelligence, 10(4), 22–29.

[1] EvaluatePharma. (2022). World Preview 2027.